Gene editing, once a staple of science fiction, is becoming a practical tool in modern medicine. After the 2023 FDA approval of Casgevy for sickle cell anemia, researchers are tackling more complex conditions, including rare neurodevelopmental disorders. One such target is Snijders Blok-Campeau syndrome, a condition that causes significant speech impairment and intellectual disability due to a single “typo” in the CHD3 gene.
The CHD3 gene helps regulate how DNA is packed and used in cells. When it malfunctions, brain cells cannot develop or migrate properly. To address this, scientists are turning to “base editing,” a newer technology that allows even more precise changes to DNA. Unlike traditional CRISPR, which acts like genetic scissors that cut through DNA strands, base editing modifies a single genetic letter without breaking the overall structure, reducing risks for sensitive brain tissue.
Recent experiments on mice showed incredible improvements in the mice’s behavior and memory. The technique proved effective even in adolescence, suggesting the brain retains a surprising ability to heal long after birth. Although delivering the proteins and enzymes used for the editing into the brain remains a challenge, this breakthrough offers hope that many genetic diseases might one day be cured with a single, precise edit.
J.K. Park Senior Reporter junior/1776299911/1613368089
1. How does the CHD3 gene influence brain cell development?
2. What is the main difference between CRISPR and base editing?
3. What improvements did scientists observe in the mouse experiments?
4. Which disease received FDA approval for gene editing in 2023?
1. Should gene editing be used to cure rare genetic disorders?
2. How do you feel about using mice for experiments?
3. Is the brains ability to heal itself truly surprising?
4. Could gene editing eventually lead to dangerous human enhancements?
Gene editing, once a staple of science fiction, is becoming a practical tool in modern medicine. After the 2023 FDA approval of Casgevy for sickle cell anemia, researchers are tackling more complex conditions, including rare neurodevelopmental disorders. One such target is Snijders Blok-Campeau syndrome, a condition that causes significant speech impairment and intellectual disability due to a single “typo” in the CHD3 gene.
